Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Oslo Study: Treatment of Mild Hypertension

      ,

      Nephron

      S. Karger AG

      Mild hypertension, Drug treatment, Five-year controlled trial

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          During 1972–1973,785 symptom-free men, aged 40–49, with mild hypertension, were randomly assigned to a 5-year controlled drug treatment study, 406 in the treatment group and 379 in the control group. The basic drug was hydrochlorothiazide, in addition methyldopa or propranolol if necessary. The mean observation time was 66 months (range 60–78). At 5 years’ follow-up there was no difference in total mortality between treated and controls, nor in cardiovascular mortality. There was a good prevention of cerebrovascular disease (0 vs. 7). Regarding coronary heart disease, however, there was an opposite trend (20 vs. 13, p > 0.10). During the trial, different drug-induced changes were observed in serum lipids, glucose and uric acid. The importance of these changes are still uncertain.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          978-3-8055-4710-9
          978-3-318-01616-1
          1660-8151
          2235-3186
          1987
          1987
          05 December 2008
          : 47
          : Suppl 1
          : 108-110
          Affiliations
          Medical Out-Patient Clinic, Ullevaal Hospital, Oslo, Norway
          Article
          184565 Nephron 1987;47:108–110
          10.1159/000184565
          3320783
          © 1987 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 3
          Categories
          Session V: Intervention Studies

          Cardiovascular Medicine, Nephrology

          Five-year controlled trial, Drug treatment, Mild hypertension

          Comments

          Comment on this article